SOPHiA GENETICS And QIAGEN Forge Partnership To Combine Strengths In Next-generation Sequencing
SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company in the healthcare space, today announced a new partnership with QIAGEN N.V. (NYSE:QGEN) that will pair QIAseq reagent technology with the SOPHiA
BTIG Initiates Coverage On Sophia Genetics with Buy Rating, Announces Price Target of $6
BTIG analyst Mark Massaro initiates coverage on Sophia Genetics (NASDAQ:SOPH) with a Buy rating and announces Price Target of $6.
Credit Suisse Initiates Coverage On Sophia Genetics with Neutral Rating, Announces Price Target of $2
Credit Suisse analyst Phil Winslow initiates coverage on Sophia Genetics (NASDAQ:SOPH) with a Neutral rating and announces Price Target of $2.
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
‘SOPHiA GENETICS Partners with Microsoft to Accelerate Multimodal Health Data Analysis’ – SEC
https://www.sec.gov/Archives/edgar/data/1840706/000095010322018818/dp183563_ex9901.htm
The agreement is to expand and reinforce data-driven medicine through the SOPHiA DDMTM health data analysis platform available
Morgan Stanley Maintains Overweight on Sophia Genetics, Lowers Price Target to $13
Morgan Stanley analyst Tejas Savant maintains Sophia Genetics (NASDAQ:SOPH) with a Overweight and lowers the price target from $14 to $13.
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.